These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 28734907)

  • 1. Predicting relapse in schizophrenia: Is BDNF a plausible biological marker?
    Pillai A; Schooler NR; Peter D; Looney SW; Goff DC; Kopelowicz A; Lauriello J; Manschreck T; Mendelowitz A; Miller DD; Severe JB; Wilson DR; Ames D; Bustillo J; Kane JM; Buckley PF
    Schizophr Res; 2018 Mar; 193():263-268. PubMed ID: 28734907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Injectable and Oral Antipsychotics in Relapse Rates in a Pragmatic 30-Month Schizophrenia Relapse Prevention Study.
    Buckley PF; Schooler NR; Goff DC; Kopelowicz A; Lauriello J; Manschreck TC; Mendelowitz A; Miller DD; Wilson DR; Ames D; Bustillo JR; Kane JM; Looney SW
    Psychiatr Serv; 2016 Dec; 67(12):1370-1372. PubMed ID: 27476806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics.
    Xiu MH; Hui L; Dang YF; Hou TD; Zhang CX; Zheng YL; Chen DC; Kosten TR; Zhang XY
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Nov; 33(8):1508-12. PubMed ID: 19720106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased plasma Brain-Derived Neurotrophic Factor (BDNF) levels in females with schizophrenia.
    Weickert CS; Lee CH; Lenroot RK; Bruggemann J; Galletly C; Liu D; Balzan R; Pillai A; Buckley P; Weickert TW
    Schizophr Res; 2019 Jul; 209():212-217. PubMed ID: 31088701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting relapse with residual symptoms in schizophrenia: A secondary analysis of the PROACTIVE trial.
    Saito Y; Sakurai H; Kane JM; Schooler NR; Suzuki T; Mimura M; Uchida H
    Schizophr Res; 2020 Jan; 215():173-180. PubMed ID: 31672387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of brain-derived neurotrophic factor and cortisol to sulfate of dehydroepiandrosterone molar ratio associated with clinical response to L-theanine as augmentation of antipsychotic therapy in schizophrenia and schizoaffective disorder patients.
    Miodownik C; Maayan R; Ratner Y; Lerner V; Pintov L; Mar M; Weizman A; Ritsner MS
    Clin Neuropharmacol; 2011; 34(4):155-60. PubMed ID: 21617527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased plasma brain-derived neurotropic factor, not nerve growth factor-Beta, in schizophrenia patients with better response to risperidone treatment.
    Lee BH; Kim YK
    Neuropsychobiology; 2009; 59(1):51-8. PubMed ID: 19270464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination Antipsychotic Therapies: An Analysis From a Longitudinal Pragmatic Trial.
    Foster A; Buckley P; Lauriello J; Looney S; Schooler N
    J Clin Psychopharmacol; 2017 Oct; 37(5):595-599. PubMed ID: 28806390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.
    Subotnik KL; Casaus LR; Ventura J; Luo JS; Hellemann GS; Gretchen-Doorly D; Marder S; Nuechterlein KH
    JAMA Psychiatry; 2015 Aug; 72(8):822-9. PubMed ID: 26107752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of antipsychotics on the serum BDNF levels in schizophrenia.
    Chen CC; Huang TL
    Psychiatry Res; 2011 Oct; 189(3):327-30. PubMed ID: 21320726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment.
    Pirildar S; Gönül AS; Taneli F; Akdeniz F
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jul; 28(4):709-13. PubMed ID: 15276697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum brain-derived neurotrophic factors in Taiwanese patients with drug-naïve first-episode schizophrenia: Effects of antipsychotics.
    Chiou YJ; Huang TL
    World J Biol Psychiatry; 2017 Aug; 18(5):382-391. PubMed ID: 27643618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An increase in plasma brain derived neurotrophic factor levels is related to n-3 polyunsaturated fatty acid efficacy in first episode schizophrenia: secondary outcome analysis of the OFFER randomized clinical trial.
    Pawełczyk T; Grancow-Grabka M; Trafalska E; Szemraj J; Żurner N; Pawełczyk A
    Psychopharmacology (Berl); 2019 Sep; 236(9):2811-2822. PubMed ID: 31098654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics.
    Tan YL; Zhou DF; Cao LY; Zou YZ; Zhang XY
    Neurosci Lett; 2005 Jul 1-8; 382(1-2):27-32. PubMed ID: 15911116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine.
    Yamamori H; Hashimoto R; Ishima T; Kishi F; Yasuda Y; Ohi K; Fujimoto M; Umeda-Yano S; Ito A; Hashimoto K; Takeda M
    Neurosci Lett; 2013 Nov; 556():37-41. PubMed ID: 24141084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal assessment of brain-derived neurotrophic factor in Sardinian psychotic patients (LABSP): a protocol for a prospective observational study.
    Primavera D; Manchia M; Deriu L; Tusconi M; Collu R; Scherma M; Fadda P; Fratta W; Carpiniello B
    BMJ Open; 2017 May; 7(5):e014938. PubMed ID: 28550022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
    Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
    Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased BDNF in patients with antipsychotic naïve first episode schizophrenia.
    Jindal RD; Pillai AK; Mahadik SP; Eklund K; Montrose DM; Keshavan MS
    Schizophr Res; 2010 Jun; 119(1-3):47-51. PubMed ID: 20096541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.